City A.M.Rare disease firm Amryt reveals a "major" gene therapy tie-up as revenues riseCity A.M.Rare and orphan disease specialist Amryt Pharma has announced a major in-lincence agreement for a novel gene therapy platform as its revenues for … Continue reading
Oncology Nurse AdvisorAge Not a Deterrent to Immunotherapy for Malignant MelanomaOncology Nurse AdvisorPatients >65 years of age with metastatic melanoma who are treated with immunotherapy do not have an increased risk for immune-related adverse eve… Continue reading
Nasdaq |
Inovio’s (INO) Q4 Loss Narrower than Expected, Revenues Beat
Nasdaq Moreover, the company also received additional $1.2 million revenues under Inovio’s prior collaboration with Roche RHHBY for the development of Inovio’s DNA immunotherapy, INO-180. However, upside in revenues was partially offset by lower grants … |
|
Arbor Biotechnologies Discovers New CRISPR System Utilizing its Discovery Platform
GlobeNewswire (press release) CAMBRIDGE, Mass., March 15, 2018 (GLOBE NEWSWIRE) — Arbor Biotechnologies, an early stage life sciences company, today published its first findings of a new member of the CRISPR-Cas13 enzyme family—Cas13d, arising from Arbor’s discovery platform. In … |
News-Medical.net |
Immunotherapy Raises the Stakes and Ovarian Cancer Blinks
Genetic Engineering & Biotechnology News “I’ll see your neoepitope and raise you a tumor-infiltrating lymphocyte.” Such bets could be placed more confidently if cancer immunotherapy would deal itself a stronger hand, one that would include the “juiciest” T cells—the T cells that are best at … Ludwig researchers extend potential for personalized immunotherapy to ovarian cancer, other tumorsNews-Medical.net |